Understanding Resistance Mechanisms and Expanding the Therapeutic Utility of PARP Inhibitors

Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial

(2017) Elizabeth M Swisher et al.   LANCET ONCOLOGY

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation

(2017) Mark Robson et al.   NEW ENGLAND JOURNAL OF MEDICINE

PARP inhibitors: Synthetic lethality in the clinic

(2017) Christopher J. Lord et al.   SCIENCE

Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers

(2017) Johann de Bono et al.   Cancer Discovery

Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer

(2017) Mark Yarchoan et al.   Oncotarget

Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer

(2016) Yvette Drew et al.   BRITISH JOURNAL OF CANCER

Randomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non–Small Cell Lung Cancer

(2016) Suresh S. Ramalingam et al.   CLINICAL CANCER RESEARCH

Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer

(2016) M. L. Telli et al.   CLINICAL CANCER RESEARCH

Targeting the ATR/CHK1 Axis with PARP Inhibition Results in Tumor Regression in BRCA -Mutant Ovarian Cancer Models

(2016) Hyoung Kim et al.   CLINICAL CANCER RESEARCH

Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial

(2016) Jonathan A Ledermann et al.   LANCET ONCOLOGY

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer

(2016) Mansoor R. Mirza et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting DNA Repair in Cancer: Beyond PARP Inhibitors

(2016) Jessica S. Brown et al.   Cancer Discovery

PARP1 inhibition radiosensitizes HNSCC cells deficient in homologous recombination by disabling the DNA replication fork elongation response

(2016) Stephanie Wurster et al.   Oncotarget

Evaluation of Concurrent Radiation, Temozolomide and ABT-888 Treatment Followed by Maintenance Therapy with Temozolomide and ABT-888 in a Genetically Engineered Glioblastoma Mouse Model

(2016) Benjamin Lemasson et al.   NEOPLASIA

Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma

(2015) M. R. Middleton et al.   ANNALS OF ONCOLOGY

mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer

(2015) W. Mo et al.   CLINICAL CANCER RESEARCH

Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer

(2015) Yung-Jue Bang et al.   JOURNAL OF CLINICAL ONCOLOGY

A randomized phase I/II study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma: an NRG oncology RTOG group study

(2015) H. Ian Robins et al.   JOURNAL OF NEURO-ONCOLOGY

Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial

(2015) Amit M Oza et al.   LANCET ONCOLOGY

Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors

(2015) T. A. Hopkins et al.   MOLECULAR CANCER RESEARCH

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer

(2015) Joaquin Mateo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer

(2015) Linda Henneman et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors

(2015) J. Shen et al.   Cancer Discovery

The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin

(2015) José Luis Ordóñez et al.   Oncotarget

CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer

(2015) T. Higuchi et al.   Cancer Immunology Research

Doubling Down on the PI3K-AKT-mTOR Pathway Enhances the Antitumor Efficacy of PARP Inhibitor in Triple Negative Breast Cancer Model beyond BRCA-ness

(2015) Pradip De et al.   NEOPLASIA

Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors

(2014) J. Balmaña et al.   ANNALS OF ONCOLOGY

Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy

(2014) Edwin Choy et al.   BMC CANCER

Combined Inhibition of Wee1 and PARP1/2 for Radiosensitization in Pancreatic Cancer

(2014) D. Karnak et al.   CLINICAL CANCER RESEARCH

ABC Transporters in Multidrug Resistance and Pharmacokinetics, and Strategies for Drug Development

(2014) Young Choi et al.   CURRENT PHARMACEUTICAL DESIGN

Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study

(2014) Joyce F Liu et al.   LANCET ONCOLOGY

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial

(2014) Jonathan Ledermann et al.   LANCET ONCOLOGY

Vulnerabilities of PTEN-TP53-Deficient Prostate Cancers to Compound PARP-PI3K Inhibition

(2014) E. Gonzalez-Billalabeitia et al.   Cancer Discovery

P-glycoprotein Inhibition as a Therapeutic Approach for Overcoming Multidrug Resistance in Cancer: Current Status and Future Perspectives

(2013) Ziyad Binkhathlan et al.   CURRENT CANCER DRUG TARGETS

Development of Therapeutic Combinations Targeting Major Cancer Signaling Pathways

(2013) Timothy A. Yap et al.   JOURNAL OF CLINICAL ONCOLOGY

Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib

(2013) J. Murai et al.   MOLECULAR CANCER THERAPEUTICS

Evaluation of poly (ADP-ribose) polymerase inhibitor ABT-888 combined with radiotherapy and temozolomide in glioblastoma

(2013) Lara Barazzuol et al.   Radiation Oncology

53BP1 Regulates DSB Repair Using Rif1 to Control 5' End Resection

(2013) M. Zimmermann et al.   SCIENCE

Rif1 Prevents Resection of DNA Breaks and Promotes Immunoglobulin Class Switching

(2013) M. Di Virgilio et al.   SCIENCE

Exploiting ecological principles to better understand cancer progression and treatment

(2013) D. Basanta et al.   Interface Focus

Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors

(2012) J. Murai et al.   CANCER RESEARCH

RNF8 Regulates Assembly of RAD51 at DNA Double-Strand Breaks in the Absence of BRCA1 and 53BP1

(2012) S. Nakada et al.   CANCER RESEARCH

Radiosensitization effect of poly(ADP-ribose) polymerase inhibition in cells exposed to low and high liner energy transfer radiation

(2012) Takahisa Hirai et al.   CANCER SCIENCE

BRCA1 Functions Independently of Homologous Recombination in DNA Interstrand Crosslink Repair

(2012) Samuel F. Bunting et al.   MOLECULAR CELL

Systematic identification of genomic markers of drug sensitivity in cancer cells

(2012) Mathew J. Garnett et al.   NATURE

Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer

(2012) Jonathan Ledermann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1 -Mutated Mouse Mammary Tumors

(2012) Janneke E. Jaspers et al.   Cancer Discovery

PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition

(2012) Yasir H. Ibrahim et al.   Cancer Discovery

Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer

(2012) Ashish Juvekar et al.   Cancer Discovery

Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors

(2011) P. Neri et al.   BLOOD

Secondary Somatic Mutations Restoring BRCA1/2 Predict Chemotherapy Resistance in Hereditary Ovarian Carcinomas

(2011) Barbara Norquist et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients WithBRCA1orBRCA2Mutations and Recurrent Ovarian Cancer

(2011) Stan B. Kaye et al.   JOURNAL OF CLINICAL ONCOLOGY

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

(2011) Karen A Gelmon et al.   LANCET ONCOLOGY

The poly(ADP-Ribose) polymerase inhibitor ABT-888 reduces radiation-induced nuclear EGFR and augments head and neck tumor response to radiotherapy

(2011) Somaira Nowsheen et al.   RADIOTHERAPY AND ONCOLOGY

The Mechanism of Double-Strand DNA Break Repair by the Nonhomologous DNA End-Joining Pathway

(2010) Michael R. Lieber   Annual Review of Biochemistry

"Contextual" Synthetic Lethality and/or Loss of Heterozygosity: Tumor Hypoxia and Modification of DNA Repair

(2010) N. Chan et al.   CLINICAL CANCER RESEARCH

Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses inBRCACarrier Ovarian Cancer Correlating With Platinum-Free Interval

(2010) Peter C. Fong et al.   JOURNAL OF CLINICAL ONCOLOGY

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

(2010) Andrew Tutt et al.   LANCET

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

(2010) M William Audeh et al.   LANCET

A Selective Requirement for 53BP1 in the Biological Response to Genomic Instability Induced by Brca1 Deficiency

(2009) Liu Cao et al.   MOLECULAR CELL

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers

(2009) Peter C. Fong et al.   NEW ENGLAND JOURNAL OF MEDICINE

Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers

(2008) Wataru Sakai et al.   NATURE

Resistance to therapy caused by intragenic deletion in BRCA2

(2008) Stacey L. Edwards et al.   NATURE

Regulation of DNA repair throughout the cell cycle

(2008) Dana Branzei et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY